Nexalin Technology, Inc.
$3.38
+0.2650 (3.85%)
Transforming Mental Health with Advanced Neurostimulation
Company Overview Listen to Overview
Nexalin Technology is a pioneering medical technology company focused on addressing the global mental health crisis through innovative neurostimulation devices. Nexalin's products, which include the Gen-2 and newly introduced Gen-3 HALO™ Clarity devices, are non-invasive and utilize advanced frequency-based stimulation to target deep brain structures associated with various mental health disorders. These disorders include but are not limited to depression, anxiety, insomnia, PTSD, and traumatic brain injuries. Nexalin's commitment to non- pharmacological treatment options is underpinned by extensive clinical research and intellectual property protections, aiming to provide significant therapeutic benefits without adverse effects. The company's approach integrates product innovation with a virtual clinic model to enhance accessibility and effectiveness of treatments, offering a significant step forward in mental healthcare.
Value Proposition Listen to Value Proposition
Nexalin Technology is revolutionizing mental health treatment with its cutting-edge, non-invasive neurostimulation technology, powered by the proprietary Deep Intracranial Frequency Stimulation (DIFS®). The Gen-3 HALO™ Clarity headset delivers high-intensity, frequency-based stimulation that uniquely penetrates deep brain structures such as the hippocampus, amygdala, and insula—key areas critical for treating mental health conditions. This advanced technology provides a safe, non-pharmacological solution with clinically validated improvements for conditions including depression, insomnia, PTSD, and Alzheimer’s disease.
Recent advancements, such as the launch of Nexalin’s Virtual Clinic, integrate AI-based solutions with the Gen-3 Halo headset, enabling patients to receive treatment from the comfort of their homes under physician supervision. This innovative platform includes an Electronic Data Capture (EDC) system and a Patient Monitoring System (PMS) for real- time data collection and personalized care, enhancing treatment accessibility and adherence.
Nexalin’s dedication to clinical research and innovation has been further validated through peer-reviewed publications showcasing its technology’s effectiveness in improving cognitive function and mental health outcomes. Key studies have demonstrated long-lasting therapeutic benefits, including enhanced brain connectivity and improved memory in Alzheimer’s patients, alongside reductions in PTSD and depression symptoms.
With robust intellectual property protections, ongoing FDA approval processes, and an expanding footprint in international markets, Nexalin is strategically positioned as an emerging leader in the $537 billion mental health market projected by 2030. Maxim initiated coverage of Nexalin in October 2024 with a buy rating and $3 price target.
Global Funded Clinical Trials in Process
Investor Presentation
Investment Highlights Listen to Investment Highlights
Innovative technology with proven clinical results
- Pioneering non-invasive, frequency-based deep brain stimulation devices targeting treatment-resistant mental health disorders including PTSD, insomnia, depression, and more
- Landmark study demonstrated improvements in memory and cognitive function for patients with mild Alzheimer’s disease using company’s proprietary technology; results published in Journal of Alzheimer’s Disease
- Recent clinical trials highlight the effectiveness of the Gen-3 Halo headset in reducing pain and improving brain activity in veterans with traumatic brain injury (TBI)
- The Gen-3 HALO™ Clarity headset enables convenient at-home treatment through Nexalin’s Virtual Clinic model; virtual care delivery eliminates barriers to accessing treatment, broadening reach and scalability
- Integrated AI-driven tools, including an Electronic Data Capture (EDC) system and Patient Monitoring System (PMS), provide real-time insights and enhance patient care
Strategically positioned to address massive market opportunity
- Mental health market projected to reach $537 billion by 2030
- Neuromodulation market expected to grow to $11 billion by 2028, addressing unmet needs for non-invasive solutions
- Recent expansion into Brazil, China, and Oman, with FDA clearance for the Gen-3 Halo headset underway to capture opportunities in new and growing markets
Strong intellectual property protections
- Strong patent portfolio, including new patents for Alzheimer’s and dementia treatments, securing key technological innovations through 2040
Experienced leadership and advisory board
- Led by CEO Mark White, an innovator in digital medical markets, supported by a highly experienced team and collaborations with leading institutions like Trial-Track and UC San Diego
- Advisory board and partnerships align with Nexalin’s mission to redefine mental healthcare and scale solutions globally
Buy rating and $3 price target from Maxim
Global Mental Health Epidemic
Sign Up For NXL Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Nexalin (NXL) is a client of RedChip Companies. NXL agreed to pay RedChip a one-time $45,000 fee for a national TV ad campaign that aired weekdays from April 1 through April 11, 2024, a one-time $40,000 fee for a national TV ad campaign aired weekdays from June 17 to June 28, 2024, a one-time $40,000 fee for a national TV ad campaign aired weekdays from October 16 to October 30, 2024, and a one-time $78,000 fee for a four-week national TV ad campaign aired weekdays from February 3 to February 28, 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.